FOCUS
For hierarchy
Cancer Precision Medicine
In this special issue, we have invited 7 reviews to discuss recent advances in precision cancer medicine, which include new PI3K/mTOR pathway inhibitors, endogenous angiogenesis inhibitors, NK cell-based cancer immunotherapy, microRNAs and alternative splicing as potential new diagnostic markers and cancer drug targets, and intra-tumor heterogeneity of cancer cells and their implications in cancer treatment. All of these studies support the new exciting development in cancer medicine in order to tailor effective cancer treatment precisely based on the molecular signatures of cancers in target.
Original Articles
DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor & antiangiogenic activity in vitro
Xiao-bin Guo, Wei Zhu, Xian-jie Chen, Lin-jiang Tong, Xia Peng, Min Huang, Hong-chun Liu, Hong Liu & Jian Ding
Acta Pharmacologica Sinica advance online publication, 1 Jun 2015; doi:10.1038/aps.2015.25
Broad H3K4me3 is associated with increased transcription elongation & enhancer activity at tumor-suppressor genes
Kaifu Chen, Zhong Chen, Dayong Wu, Lili Zhang, Xueqiu Lin, Jianzhong Su, Benjamin Rodriguez, Yuanxin Xi, Zheng Xia, Xi Chen, Xiaobing Shi, Qianben Wang & Wei Li
Nature Genetics advance online publication, 24 August 2015; doi:10.1038/ng.3385
The breast tumor microenvironment alters the phenotype & function of natural killer cells
Tamara Krneta, Amy Gillgrass, Marianne Chew & Ali A. Ashkar
Cellular & Molecular Immunology advance online publication, 17 August 2015; doi:10.1038/cmi201542
Reviews
PI3K isoform-selective inhibitors: next-generation targeted cancer therapies
Xiang Wang, Jian Ding & Ling-hua Meng
Acta Pharmacologica Sinica advance online publication, 14 Sep 2015; doi:10.1038/aps.2015.71
Novel endogenous angiogenesis inhibitors & their therapeutic potential
Nithya Rao, Yu Fei Lee & Ruowen Ge
Acta Pharmacologica Sinica advance online publication, 14 Sep 2015; doi:10.1038/aps.2015.73
Natural killer cell dysfunction in hepatocellular carcinoma & NK cell-based immunotherapy
Cheng Sun, Hao-yu Sun, Wei-hua Xiao, Cai Zhang & Zhi-gang Tian
Acta Pharmacologica Sinica advance online publication, 15 Jun 2015; doi:10.1038/aps.2015.41
Intra-tumor heterogeneity of cancer cells & its implications for cancer treatment Open
Xiao-xiao Sun & Qiang Yu
Acta Pharmacologica Sinica advance online publication, 21 Sep 2015; doi:10.1038/aps.2015.92
Precision medicine for metastatic breast cancer-limitations & solutions
Monica Arnedos, Cecile Vicier, Sherene Loi, Celine Lefebvre, Stefan Michiels, Herve Bonnefoi & Fabrice Andre
Nature Reviews Clinical Oncology advance online publication, 21 July 2015 ; doi:10.1038/nrclinonc.2015.123
PI3K and cancer: lessons, challenges & opportunities
David A. Fruman & Christian Rommel
Nature Reviews Drug Discovery 13: 140–156; doi:10.1038/nrd4204
partner of 
